BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27376763)

  • 21. Predictive Parameters Identifying Men Eligible for a Sole MRI/Ultrasound Fusion-Guided Targeted Biopsy without an Additional Systematic Biopsy.
    Günzel K; Haas M; Maxeiner A; Stephan C; Buckendahl J; Asbach P; Miller K; Kempkensteffen C; Cash H
    Urol Int; 2017; 98(1):15-21. PubMed ID: 27618633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.
    García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A
    Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
    Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
    BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy.
    Ploussard G; Nicolaiew N; Marchand C; Terry S; Vacherot F; Vordos D; Allory Y; Abbou CC; Salomon L; de la Taille A
    Eur Urol; 2014 Jan; 65(1):154-61. PubMed ID: 22698576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer detection rate at second and third biopsy. Predictive factors and risk groups for cancer diagnosis.
    Castello-Porcar A; García-Morata F; Martinez-Jabaloyas JM
    Arch Esp Urol; 2014 Sep; 67(7):605-14. PubMed ID: 25241833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10 ng/ml: results of 564 consecutive cases.
    Porcaro AB; Tafuri A; Sebben M; Shakir A; Novella G; Pirozzi M; Processali T; Rizzetto R; Amigoni N; Tiso L; Cerrato C; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
    Ther Adv Urol; 2019; 11():1756287219868604. PubMed ID: 31452688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prospective validation of a nomogram predictive of a positive initial prostate biopsy].
    Ramírez-Backhaus M; Bahilo P; Arlandis S; Santamaría Navarro C; Pontones Moreno JL; Jiménez-Cruz F
    Actas Urol Esp; 2010 Jan; 34(1):35-42. PubMed ID: 20223131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low risk patients benefit from extreme anterior apical sampling on initial biopsy for prostate cancer diagnosis.
    Elshafei A; Kartha G; Li Y; S Moussa A; Hatem A; Gao T; Jones JS
    Prostate; 2014 Sep; 74(12):1183-8. PubMed ID: 24962004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
    BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
    Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
    Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
    Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
    Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
    Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Wolters T; Roobol MJ; Bangma CH; Schröder FH
    Eur Urol; 2009 Feb; 55(2):385-92. PubMed ID: 18353529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
    Campos-Fernandes JL; Bastien L; Nicolaiew N; Robert G; Terry S; Vacherot F; Salomon L; Allory Y; Vordos D; Hoznek A; Yiou R; Patard JJ; Abbou CC; de la Taille A
    Eur Urol; 2009 Mar; 55(3):600-6. PubMed ID: 18597923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy?
    Elshafei A; Moussa AS; Hatem A; Ethan V; Panumatrassamee K; Hernandez AV; Jones JS
    Urology; 2013 Apr; 81(4):826-30. PubMed ID: 23434102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-void residual urinary volume is an independent predictor of biopsy results in men at risk for prostate cancer.
    Cormio L; Lucarelli G; Netti GS; Stallone G; Selvaggio O; Troiano F; Di Fino G; Sanguedolce F; Bufo P; Grandaliano G; Carrieri G
    Anticancer Res; 2015 Apr; 35(4):2175-82. PubMed ID: 25862875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
    Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
    Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.